Janet Pope Janetbirdope
4 years 5 months ago
#ClinicalPearl Overall #azathioprine wins for maintenance of remission in ANCA associated #vasculitis with equal remission in MPO+ but less with AZA inPR3+. So use AZA but if not tolerated sometimes MMF is ok. Otherwise consider #Leflunomide or if bad organ involvement #Rituximab https://t.co/efi8cKQ36B
Dr. John Cush RheumNow
4 years 5 months ago
ALEVIATE - small study of Alemtuzumab (anti-CD52) in 23 refractory ANCA-Assoc vasculitis or Behcets— 16/23 (70%) had either complete (6/23, 26%) or partial (10/23, 44%) response at 6 months. 10 SAE in 7 (30%) pts https://t.co/EciG0Mkn4i https://t.co/7UmDA4NxqV
Dr. John Cush RheumNow
4 years 5 months ago
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/is2O1dewcr
Dr. John Cush RheumNow
4 years 5 months ago
Network metaanalysis studied 46 RCTs biologics in #PsA. Some TNFi's numerically (not signif) better vsn interleukin inhib for ACR resps, but worse on PASI resps (IL-23, IL-17i had better PASI responses); No diff in enthesitis & dactylitis resps https://t.co/AvnoLRVi6C #PsAlways https://t.co/BSl9hVbIx6
Dr. John Cush RheumNow
4 years 5 months ago
Metanlysis of psychological interventions for chronic low back pain (97 RCTs, 13,136 pts) finds that Only behavioural therapy delivered w/ physiotherapy care (mainly structured exercise) reduced pain intensity up (high quality evidence) https://t.co/wHHvj0vey9 https://t.co/PBwyitTZxK
A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis.
Dr. John Cush RheumNow
4 years 5 months ago
211 pts presenting w/ hot swollen joint to the ER; 28 w/ septic arthritis; pseudogout 32; gout 50; & others: 101. Predictors of Septic Arthritis: RA (OR 3.4); skin infx (OR 3.3); liver Dz (OR 9.9); knee involv (OR 3.5); immunosuppressive use (OR 3.5) https://t.co/uASovNVOWb https://t.co/Fq3obVDavm
Dr. John Cush RheumNow
4 years 5 months ago
TONIGHT! Join us for Tuesday Night Rheumatology on April 5 at 7pm ET. Register today! https://t.co/jewQ9RE88n https://t.co/EfFiztByub
Without question, basic immunology is at the foundation of rheumatology as a discipline. Indeed, for many rheumatologists, it was the intricacies of the immune system that attracted us into the field. With each passing year, extraordinary advances in scientific methods begat tremendous gains in our understanding of the immune system. Excitingly, we may be entering a new era, driven by results in psoriatic arthritis and other related
Richard Conway RichardPAConway
4 years 5 months ago
15 RTX patients with no response to 2 doses of SARS-CoV-2 vaccine received a booster. Despite persistent B-cell depletion 7/15 had a response to booster vaccine #Vasculitis22 https://t.co/y8y8Bjnqtp
Eric Topol EricTopol
4 years 5 months ago
The BA.2 variant is now dominant in every region of the United States and accounts for 72% overall for new Covid cases
https://t.co/jjl2AnwOWX @CDCgov https://t.co/ot1GNez51W
Dr. John Cush RheumNow
4 years 5 months ago
Your Psoriatic Questions from RNL 2022
Dr. Jack Cush fields Rheumatologists questions from RNL 2022
QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022.
https://t.co/DlW5KA3mEo https://t.co/wtTlYJs89l
Dr. John Cush RheumNow
4 years 5 months ago
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/PlUfbo8FNd
Dr. John Cush RheumNow
4 years 5 months ago
Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/1JjsDTZX57 #PsA #PsAlways https://t.co/H3AM4Nn2I0

